Radiotherapy prolongs the survival of advanced non-smallcell lung cancer patients undergone to an immune-modulating treatment with dose-fractioned cisplatin and metronomic etoposide and bevacizumab (mPEBev)
dc.creator | Pastina, P | |
dc.creator | Nardone, V | |
dc.creator | Botta, C | |
dc.creator | Croci, S | |
dc.creator | Tini, P | |
dc.creator | Battaglia, G | |
dc.creator | Ricci, V | |
dc.creator | Cusi, MG | |
dc.creator | Gandolfo, C | |
dc.creator | Misso, G | |
dc.creator | Zappavigna, S | |
dc.creator | Caraglia, M | |
dc.creator | Giordano, A | |
dc.creator | Aldinucci, D | |
dc.creator | Tassone, P | |
dc.creator | Tagliaferri, P | |
dc.creator | Pirtoli, L | |
dc.creator | Correale, P | |
dc.date.accessioned | 2021-01-25T20:54:18Z | |
dc.date.available | 2021-01-25T20:54:18Z | |
dc.date.issued | 2017-01-01 | |
dc.identifier.issn | 1949-2553 | |
dc.identifier.issn | 1949-2553 | |
dc.identifier.doi | http://dx.doi.org/10.34944/dspace/4954 | |
dc.identifier.other | FI5ZG (isidoc) | |
dc.identifier.other | 29100279 (pubmed) | |
dc.identifier.uri | http://hdl.handle.net/20.500.12613/4972 | |
dc.description.abstract | © Pastina et al. Radiotherapy (RT), together with a direct cytolytic effect on tumor tissue, also elicits systemic immunological events, which sometimes result in the regression of distant metastases (abscopal effect). We have shown the safety and anti-tumor activity of a novel metronomic chemotherapy (mCH) regimen with dose-fractioned cisplatin, oral etoposide and bevacizumab, a mAb against the vasculo-endothelial-growthfactor (mPEBev regimen), in metastatic non-small-cell-lung cancer (mNSCLC). This regimen, designed on the results of translational studies, showed immune-modulating effects that could trigger and empower the immunological effects associated with tumor irradiation. In order to assess this, we carried out a retrospective analysis in a subset of 69 consecutive patients who received the mPEBev regimen within the BEVA2007 trial. Forty-five of these patients, also received palliative RT of one or more metastatic sites. Statistical analysis (a Log-rank test) revealed a much longer median survival in the group of patients who received RT [mCH vs mCH + RT: 12.1 +/-2.5 (95%CI 3.35-8.6) vs 22.12 +/-4.3 (95%CI 11.9-26.087) months; P=0.015] with no difference in progression-free survival. In particular, their survival correlated with the mPEBev regimen ability to induce the percentage of activated dendritic cells (DCs) (CD3-CD11b+CD15-CD83+CD80+) [Fold to baseline value (FBV) ≤1 vs > 1: 4+/-5.389 (95%CI,0-14.56) vs 56+/-23.05 (95%CI,10.8-101.2) months; P:0.049)] and central-memory-T-cells (CD3+CD8+CD45RA-CCR7+) [FBV ≤1 vs > 1: 8+/-5.96 (95%CI,0-19.68) vs 31+/-12.3 (95%CI,6.94-55.1) months; P:0.045]. | |
dc.format.extent | 75904-75913 | |
dc.language.iso | en | |
dc.relation.haspart | Oncotarget | |
dc.relation.isreferencedby | Impact Journals, LLC | |
dc.rights | CC BY | |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/ | |
dc.subject | immune-modulation | |
dc.subject | radiation therapy | |
dc.subject | metronomic chemotherapy | |
dc.subject | NSCLC | |
dc.subject | retrospective analysis | |
dc.title | Radiotherapy prolongs the survival of advanced non-smallcell lung cancer patients undergone to an immune-modulating treatment with dose-fractioned cisplatin and metronomic etoposide and bevacizumab (mPEBev) | |
dc.type | Article | |
dc.type.genre | Journal Article | |
dc.relation.doi | 10.18632/oncotarget.20411 | |
dc.ada.note | For Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.edu | |
dc.creator.orcid | Giordano, Antonio|0000-0002-5959-016X | |
dc.date.updated | 2021-01-25T20:54:13Z | |
refterms.dateFOA | 2021-01-25T20:54:18Z |